Case report: TP53 c.848G>A germline mutation as a possible screening target at initial diagnosis for acute lymphoblastic leukemia

References

• Wahlin A. Accumulating evidence for a role of p53 in multiple drug resistant acute myeloid leukemia. Leuk Lymphoma. 2008;49(3):383–84. doi:10.1080/10428190801950041
   PubMed Web of Science ®Google Scholar
• Bug G. Reactivating hope for tp53-mutated acute myeloid leukaemia? Lancet Haematol. 2023;10(4):e239–40. doi:10.1016/S2352-3026(23)00028-5
   PubMed Web of Science ®Google Scholar
• Stengel A, Kern W, Haferlach T, et al. The impact of tp53 mutations and tp53 deletions on survival varies between aml, all, mds and cll: an analysis of 3307 cases. Leukemia. 2017;31(3):705–11. doi:10.1038/leu.2016.263
   PubMed Web of Science ®Google Scholar
• Rucker FG, Schlenk RF, Bullinger L, et al. Tp53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114–21. doi:10.1182/blood-2011-08-375758
   PubMed Web of Science ®Google Scholar
• Chen S, Wu JL, Liang Y, et al. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site. Cancer Cell. 2021;39(2):225–39. doi:10.1016/j.ccell.2020.11.013
   PubMed Web of Science ®Google Scholar
• Lasham A, Knowlton N, Mehta SY, et al. Breast cancer patient prognosis is determined by the interplay between tp53 mutation and alternative transcript expression: insights from tp53 long amplicon digital pcr assays. Cancers (Basel). 2021;13(7):1531. doi:10.3390/cancers13071531
   PubMed Web of Science ®Google Scholar
• Hosking FJ, Dobbins SE, Houlston RS. Genome-wide association studies for detecting cancer susceptibility. Br Med Bull. 2011;97:27–46. doi:10.1093/bmb/ldq038
   PubMed Web of Science ®Google Scholar
• Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4(3):177–83. doi:10.1038/nrc1299
   PubMed Web of Science ®Google Scholar
• Zhang P, Kitchen-Smith I, Xiong L, et al. Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression, and drug response. Cancer Res. 2021;81(7):1667–80. doi:10.1158/0008-5472.CAN-20-0177
   PubMed Web of Science ®Google Scholar
• Halldorsdottir AM, Lundin A, Murray F, et al. Impact of tp53 mutation and 17p deletion in mantle cell lymphoma. Leukemia. 2011;25(12):1904–08. doi:10.1038/leu.2011.162
   PubMed Web of Science ®Google Scholar
• Young KH, Leroy K, Moller MB, et al. Structural profiles of tp53 gene mutations predict clinical outcome in diffuse large b-cell lymphoma: an international collaborative study. Blood. 2008;112(8):3088–98. doi:10.1182/blood-2008-01-129783
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of tp53 in diffuse large b-cell lymphoma patients treated with r-chop: report from an international dlbcl rituximab-chop consortium program study. Blood. 2012;120(19):3986–96. doi:10.1182/blood-2012-05-433334
   PubMed Web of Science ®Google Scholar
• Pommert L, Burns R, Furumo Q, et al. Novel germline traf3ip3 mutation in a dyad with familial acute b lymphoblastic leukemia. Cancer Rep (Hoboken). 2021;4(3):e1335. doi:10.1002/cnr2.1335
   PubMedGoogle Scholar
• Franca R, Zudeh G, Lucafo M, et al. Genome wide association studies for treatment-related adverse effects of pediatric acute lymphoblastic leukemia. Wires Mech Dis. 2021;13(3):e1509), doi:10.1002/wsbm.1509
   PubMedGoogle Scholar
• Gambale A, Russo R, Andolfo I, et al. Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition. Clin Genet. 2019;96(4):359–65. doi:10.1111/cge.13600
   PubMed Web of Science ®Google Scholar
• Postel M, Roosen A, Laurent-Puig P, et al. Droplet-based digital pcr and next generation sequencing for monitoring circulating tumor dna: a cancer diagnostic perspective. Expert Rev Mol Diagn. 2018;18(1):7–17. doi:10.1080/14737159.2018.1400384
   PubMed Web of Science ®Google Scholar
• Stengel A, Schnittger S, Weissmann S, et al. Tp53 mutations occur in 15.7% of all and are associated with myc-rearrangement, low hypodiploidy, and a poor prognosis. Blood. 2014;124(2):251–58. doi:10.1182/blood-2014-02-558833
   PubMed Web of Science ®Google Scholar
• Kanagal-Shamanna R, Jain P, Takahashi K, et al. Tp53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-cvad-based regimens. Cancer. 2017;123(19):3717–24. doi:10.1002/cncr.30810
   PubMed Web of Science ®Google Scholar
• Muhlbacher V, Zenger M, Schnittger S, et al. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high tp53 mutation frequency of 93%. Genes Chromosomes Cancer. 2014;53(6):524–36. doi:10.1002/gcc.22163
   PubMed Web of Science ®Google Scholar
• Brown NJ, Bhatia K, Teague J, et al. Report of a bi-allelic truncating germline mutation in tp53. Fam Cancer. 2019;18(1):101–04. doi:10.1007/s10689-018-0087-1
   PubMed Web of Science ®Google Scholar
• Sato H, Matsuo S, Ando Y, et al. Germline tp53 c.566c>t mutation incidentally diagnosed during treatment for acute myeloid leukemia: a case report. Clin Case Rep. 2021;9(12):e5221. doi:10.1002/ccr3.5221
   Web of Science ®Google Scholar
• Winter G, Kirschner-Schwabe R, Groeneveld-Krentz S, et al. Clinical and genetic characteristics of children with acute lymphoblastic leukemia and li-fraumeni syndrome. Leukemia. 2021;35(5):1475–79. doi:10.1038/s41375-021-01163-y
   PubMed Web of Science ®Google Scholar
• Hill GR, Betts BC, Tkachev V, et al. Current concepts and advances in graft-versus-host disease immunology. Annu Rev Immunol. 2021;39:19–49. doi:10.1146/annurev-immunol-102119-073227
   PubMed Web of Science ®Google Scholar
• Zhang XH, Chen J, Han MZ, et al. The consensus from the Chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14(1):145. doi:10.1186/s13045-021-01159-2
   PubMed Web of Science ®Google Scholar
• Algwaiz G, Aljurf M, Koh M, et al. Real-world issues and potential solutions in hematopoietic cell transplantation during the covid-19 pandemic: perspectives from the worldwide network for blood and marrow transplantation and center for international blood and marrow transplant research health services and international studies committee. Biol Blood Marrow Transplant. 2020;26(12):2181–89. doi:10.1016/j.bbmt.2020.07.021
   PubMed Web of Science ®Google Scholar
• Saito K, Yokogami K, Maekawa K, et al. High-resolution melting effectively pre-screens for tp53 mutations before direct sequencing in patients with diffuse glioma. Hum Cell. 2021;34(2):644–53. doi:10.1007/s13577-020-00471-2
   PubMed Web of Science ®Google Scholar
• Marker DF, Agnihotri S, Amankulor N, et al. The dominant tp53 hotspot mutation in idh -mutant astrocytoma, r273c, has distinctive pathologic features and sex-specific prognostic implications. Neurooncol Adv. 2022;4(1):b182), doi:10.1093/noajnl/vdab182
   Google Scholar
• Fulci G, Ishii N, Maurici D, et al. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283 h tp53 germ-line mutation: evidence for a precursor lesion. Cancer Res. 2002;62(10):2897–905.
   PubMed Web of Science ®Google Scholar
• Wang K, Li B, Guo Y, et al. An integrated digital pcr system with high universality and low cost for nucleic acid detection. Front Bioeng Biotechnol. 2022;10:947895. doi:10.3389/fbioe.2022.947895
   PubMed Web of Science ®Google Scholar
• Frazzi R, Bizzarri V, Albertazzi L, et al. Droplet digital pcr is a sensitive tool for the detection of tp53 deletions and point mutations in chronic lymphocytic leukaemia. Br J Haematol. 2020;189(2):e49–52. doi:10.1111/bjh.16442
   PubMed Web of Science ®Google Scholar